Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report released on Wednesday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

Shares of EGRX stock opened at $0.75 on Wednesday. The company has a 50 day moving average price of $2.01 and a 200 day moving average price of $3.72. Eagle Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $9.89.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Perceptive Advisors LLC purchased a new position in Eagle Pharmaceuticals during the 2nd quarter worth $971,000. Vanguard Group Inc. boosted its stake in shares of Eagle Pharmaceuticals by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock worth $3,358,000 after purchasing an additional 2,630 shares during the last quarter. Creative Planning acquired a new stake in shares of Eagle Pharmaceuticals during the 3rd quarter worth about $59,000. Price T Rowe Associates Inc. MD purchased a new position in shares of Eagle Pharmaceuticals during the 1st quarter worth about $83,000. Finally, Fidelis Capital Partners LLC purchased a new position in shares of Eagle Pharmaceuticals during the 2nd quarter worth about $71,000. Institutional investors and hedge funds own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.